- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06742801
Étude clinique Onyx™ Liquid Embolic IDE
Étude clinique PELE IDE, sécurité embolique liquide Peripheral Onyx™ et efficacité de l'Onyx™ LES pour l'embolisation de l'hémorragie artérielle dans le système vasculaire périphérique
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.
Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.
This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Liza Marie
- Numéro de téléphone: 7072172314
- E-mail: liza.marie@medtronic.com
Sauvegarde des contacts de l'étude
- Nom: Janki Shah
- Numéro de téléphone: 7322662503
- E-mail: janki.shah@medtronic.com
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Recrutement
- Mayo Clinic
-
Contact:
- Debbie Ryan
- Numéro de téléphone: 480-342-1208
- E-mail: ryan.debra29@mayo.edu
-
Chercheur principal:
- Sadeer Alzubaidi, MD
-
Contact:
- Yahaira Parker
-
-
California
-
Irvine, California, États-Unis, 92627
- Recrutement
- University of California, Irvine
-
Contact:
- Nadine Jaoudeh, MD
- E-mail: nadine@hs.uci.edu
-
Contact:
- Kimberly Padilla
- E-mail: kpadill6@hs.uci.edu
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- University of California Los Angeles
-
Contact:
- Renato Escobar
- E-mail: raescobar@mednet.ucla.edu
-
Chercheur principal:
- Jessica Stewart, MD
-
Palo Alto, California, États-Unis, 94304
- Recrutement
- Stanford Medical Center
-
Contact:
- Andrew Picel, MD
-
Contact:
- Abigail Bond
- E-mail: abond02@stanford.edu
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- UCHealth University of Colorado Hospital
-
Contact:
- Alejandra Aguilar, MPH
- E-mail: alejandra.aguilar@cuanschutz.edu
-
Chercheur principal:
- Eduardo Bent Robinson, MD
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- Recrutement
- Yale New Haven
-
Contact:
- Patricia Fugal
- E-mail: patricia.fugal@yale.edu
-
Contact:
- Angelo Marino, MD
- E-mail: angelo.marino@yale.edu
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago
-
Contact:
- Tiana Jackson
- E-mail: tiana.jackson@bsd.uchicago.edu
-
Chercheur principal:
- Brian Funaki, MD
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Recrutement
- University of Iowa Hospitals and Clinics
-
Chercheur principal:
- Michael Hummel, MD
-
Contact:
- Victoria Mendoza
- E-mail: victoria-mendoza@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Masschusetts General Hospital
-
Contact:
- Vincent Wu, MD
- E-mail: vwu3@mgh.harvard.edu
-
Contact:
- Justin Hill
- E-mail: jhill43@mgh.harvard.edu
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68124
- Recrutement
- CHI Health Creighton University Medical Center-Bergan-Mercy
-
Contact:
- Janice Mitchel
- Numéro de téléphone: 402-619-9402
- E-mail: jan.mitchell@commonspirit.org
-
Chercheur principal:
- Patrick Harty
-
-
New Jersey
-
Newark, New Jersey, États-Unis, 07103
- Recrutement
- Rutgers New Jersey Medical School
-
Chercheur principal:
- Abhishek Kumar, MD
-
Contact:
- Saharsh Patel
- E-mail: ssp186@gsbs.rutgers.edu
-
-
New York
-
Albany, New York, États-Unis, 12208
- Recrutement
- Albany Medical Center
-
Contact:
- Nancy Spencer, NP
- E-mail: spencen@amc.edu
-
Contact:
- Gary Siskin, MD
- E-mail: sisking@amc.edu
-
New York, New York, États-Unis, 10029
- Recrutement
- The Mount Sinai
-
Contact:
- Rajesh Patel, MD
- E-mail: rajesh.patel@mountsinai.org
-
Contact:
- Aaron Greenberg
- E-mail: aaron.greenberg@mountsinai.org
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- Recrutement
- University of North Carolina at Chapel Hill
-
Chercheur principal:
- Nima Kokabi, MD
-
Contact:
- Adriana Delgado
- E-mail: adriana_delgado@med.unc.edu
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Recrutement
- University Hospitals Cleveland Medical Center
-
Contact:
- Lauren Hahn
- E-mail: lauren.hahn@uhhospitals.org
-
Chercheur principal:
- Salim Abboud, MD
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- The Ohio State University
-
Contact:
- Mina Makary, MD
-
Contact:
- Gage Spears
- E-mail: gage.spears@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15237
- Recrutement
- University of Pittsburgh Medical Center
-
Chercheur principal:
- Paula Novelli, MD
-
Contact:
- Suzanne Burdin
- E-mail: burdins@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37212
- Recrutement
- Vanderbilt University Medical Center
-
Contact:
- Celia Nunez
- Numéro de téléphone: 615-322-4559
- E-mail: celia.m.nunez@vumc.org
-
Chercheur principal:
- Anthony Borgmann, MD
-
-
Texas
-
Dallas, Texas, États-Unis, 75235
- Recrutement
- Univ Of Texas Southwestern
-
Chercheur principal:
- Sanjeeva Kalva, MD
-
Contact:
- Camille Harry
- Numéro de téléphone: 214-648-8986
- E-mail: camille.harry@utsouthwestern.edu
-
Houston, Texas, États-Unis, 77030
- Recrutement
- The University of Texas Health Science Center at Houston
-
Contact:
- Praneeth Nadimpalli
- E-mail: praneeth.v.nadimpalli@uth.tmc.edu
-
Contact:
- Lauren McGuire, RN
- E-mail: lauren.c.mcguire@uth.tmc.edu
-
Chercheur principal:
- Rodrick Zvavanjanja, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patient is ≥ 22 years old.
-
Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.
In this study, peripheral vasculature is defined as outside the brain and heart.
-
Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.
-
Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.
-
Target treatment area is free from prior embolization treatment.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Symptoms of active infection.
- Patient is known to be participating in the study of an investigational drug, biologic, or device.
- Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
- Known allergy to components of Onyx™.
- Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
- More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment with Onyx LES
Device; embolization with liquid embolic |
The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Freedom from Arterial Hemorrhage
Délai: Through 30 days post-index procedure
|
Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days. |
Through 30 days post-index procedure
|
|
Freedom from System-related Major Adverse Events (MAE)
Délai: Through 30 days post-index procedure
|
The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC. |
Through 30 days post-index procedure
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Procedural Success
Délai: At the completion of the index procedure
|
successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure. |
At the completion of the index procedure
|
|
Technical Success
Délai: At the completion of the index procedure
|
Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment. |
At the completion of the index procedure
|
|
Reintervention
Délai: Through 30 days post-index procedure
|
Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure. |
Through 30 days post-index procedure
|
|
Transfusions
Délai: Through 30 days post-index procedure
|
Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected. |
Through 30 days post-index procedure
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Ancillary Endpoint
Délai: Through index procedure
|
Duration of the index procedure |
Through index procedure
|
|
Ancillary Endpoint
Délai: Through 30 days post-index procedure
|
Length of hospitalization, post-index procedure |
Through 30 days post-index procedure
|
|
Ancillary Endpoint
Délai: Through 30 days post-index procedure
|
Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions |
Through 30 days post-index procedure
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Osman Ahmed, MD, University of Chicago
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MDT21044
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .